This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meisel, C. Articles by Stangl, K. Search for Related Content PubMed PubMed Citation Articles by Meisel, C. Articles by Stangl, K.

Role of Kozak sequence polymorphism of platelet glycoprotein Ib as a risk factor for coronary artery disease and catheter interventions

Christian Meisel, MD^*, Vahid Afshar-Kharghan, MD, Ingolf Cascorbi, MD, PhD^*, Michael Laule, MD, Verena Stangl, MD, Stefan B. Felix, MD, Gert Baumann, MD, José A. López, MD, Ivar Roots, MD^* and Karl Stangl, MD

^* Institute of Clinical Pharmacology, Berlin, Germany
Department of Cardiology, Charité University Medical Center, Campus Mitte, Humboldt University of Berlin, Berlin, Germany
Departments of Medicine and Molecular and Human Genetics, Baylor College of Medicine and Veterans Affairs Medical Center, Houston, Texas, USA

View larger version (9K): [in a new window]   Figure 1 Glycoprotein Ib–Kozak sequence genotype predicts increased relative risk for the 30-day composite end point after percutaneous transluminal coronary angioplasty (PTCA), but not after directional coronary atherectomy (DCA) or stenting. The figure shows relative risks for the GP Ib–Kozak sequence (C/C + C/T) genotype, with 95% confidence intervals (CI) adjusted for common risk factors, procedural determinants and indicators of procoagulant activation and endothelial function (see text).